ASCO 2024: Focus on Lung Cancer
ASCO 2024: Focus on Lung Cancer
Advertisement
Leah LawrenceNon-Small Cell Lung Cancer | July 12, 2024
Researchers compared outcomes between patients with baseline stage III N2 and non-N2 NSCLC.
Read More
Katie KoskoASCO 2024: Focus on Lung Cancer | July 8, 2024
Most patients who received adjuvant osimertinib achieved MRD negativity.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 5, 2024
More than half of patients in the study had psychological distress as well as elevated serum cortisol levels.
Katie KoskoASCO 2024: Focus on Lung Cancer | July 4, 2024
Researchers assessed patients' functional health and well-being across multiple physical and mental domains.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 3, 2024
A pilot study evaluated neoadjuvant platinum, pemetrexed, and nivolumab followed by pleurectomy/decortication.
Leah LawrenceASCO 2024: Focus on Lung Cancer | July 2, 2024
Study investigators say the results support further study of the bispecific T-cell engager in previously treated SCLC.
David R. Spigel, MDASCO 2024: Focus on Lung Cancer | July 1, 2024
Dr. Spigel speaks about how the American Society of Clinical Oncology Annual Meeting inspires collaboration and discovery.
Narjust Florez, MD, FASCOASCO 2024: Focus on Lung Cancer | June 27, 2024
Narjust Florez, MD, FASCO, discusses her research on the unique needs of young patients with lung cancer.
Laila Gharzai, MDASCO 2024: Focus on Lung Cancer | June 27, 2024
Laila Gharzai, MD, discusses her research on the financial impacts of lung biomarker testing.
Eric Singhi, MDASCO 2024: Focus on Lung Cancer | June 26, 2024
Dr. Singhi discusses practice-changing data and historic advancements in lung cancer.
Minesh P. Mehta, MDLung Cancer | June 25, 2024
Dr. Mehta discusses the study, which met its primary end point, and future directions for the research.
Samantha Armstrong, MDASCO 2024: Focus on Lung Cancer | July 10, 2024
Samantha Armstrong, MD, and Karine Tawagi, MD, discuss the interview on the groundbreaking plenary presentation.
Katie KoskoASCO 2024: Focus on Lung Cancer | June 24, 2024
Nearly 80% of patients enrolled had epithelioid histology and 65% had an ECOG performance status of 1.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 24, 2024
An analysis of the phase 3 trial evaluated multiple aspects of health-related quality of life.
Katie KoskoASCO 2024: Focus on Lung Cancer | June 20, 2024
The study showed that patients with certain types of insurance had significantly shorter overall survival.
Katie KoskoASCO 2024: Focus on Lung Cancer | June 20, 2024
Certain patients appeared to derive the greatest benefit from the therapy.
Leah LawrenceASCO 2024: Focus on Lung Cancer | June 18, 2024
The study "confirmed the role of adagrasib compared to docetaxel" in terms of PFS, response rate, and intracranial response.
Balazs Halmos, MDASCO 2024: Focus on Lung Cancer | June 17, 2024
Dr. Halmos hopes to see lung-focused updates take center stage again at next year's annual meeting.
Narjust Florez, MD, FASCOASCO 2024: Focus on Lung Cancer | June 14, 2024
Dr. Florez speaks about her presentation titled "Excluded, Forgotten, and Understudied: The Reality of Lung Cancer in Women."
Nicolas Girard, MD, PhDASCO 2024: Focus on Lung Cancer | June 12, 2024
The phase 2 trial evaluated subcutaneous amivantamab and lazertinib as a first-line therapy for EGFR-mutated NSCLC.
Advertisement
Advertisement
Advertisement
Latest News

July 12, 2024